Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Gastrointestinal 9Head & Neck 8Breast 5Gynecologic 4Dermatologic 3Other solid neoplasm 2Genitourinary 2Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Temozolomide 147Radiotherapy 91Cyclophosphamide 53Magnetic Resonance Spectroscopy 43Radiation 42Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 27Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 19Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × budigalimab × CNS × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡